Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection

Colin Collins's Biography



Colin Collins, Professor, University of British Columbia; Senior Scientist, Vancouver Prostate Centre

Dr. Collins obtained a PhD in Medical Genetics from the University of British Columbia after which he became faculty at Lawrence Berkeley National Laboratory (LBNL). At LBNL Dr. Collins was a cofounder of the Resource for Molecular Cytogenetics in the Department of Life Sciences. In 1998 Dr. Collins moved to the University of California San Francisco’s (UCSF) Comprehensive Cancer Center. At UCSF Dr. Collins invented and patented “paired end sequencing” and was the first to sequence a tumor genome. He also was the first to show that genome copy number aberrations can be used to risk stratify men with prostate cancer for metastasis. This work also received a patent. In 2009 Dr. Collins relocated to the University of British Columbia (UBC) and the Vancouver Prostate Centre (VPC). At the VPC Dr. Collins Directs the Laboratory for Advanced Genome Analysis (LAGA) and the BGI-VPC Joint Research Laboratory. These support genome and computational biology research within the VPC, Canada and internationally. It also supports a precision oncology program at the VPC. Dr. Collins has a keen interest in treatment resistant prostate cancer where he and his collaborators have made key discoveries into the mechanisms of therapeutic resistance, identification of novel therapeutic targets and the development of liquid biopsies for prostate and other cancers. Dr. Collins has appointments at Simon Fraser University in the School of Computing Science and at BGI in the Think Tank Division. He has over 190 publications and multiple patents.

Colin Collins Image

Predicting The Course of Prostate Cancer

Thursday, 29 March 2018 at 18:30

Add to Calendar ▼2018-03-29 18:30:002018-03-29 19:30:00Europe/LondonPredicting The Course of Prostate CancerSELECTBIOenquiries@selectbiosciences.com

Dr. Collins will discuss recent insights into the mechanisms that drive prostate cancer progression with emphasis on stomal determinants of metastasis. In addition, he will discuss liquid biopsies for monitoring resistance to therapy.


Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Nucleic Acids and Circulating Rare Cells: Liquid Biopsy for Early Cancer Detection SELECTBIOenquiries@selectbiosciences.com